Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
Centene
CNC
Centene
Medicare And Medicaid Expansion Will Unlock Long-Term Healthcare Potential
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 16 Analysts
Published
11 May 25
Updated
06 Aug 25
2
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
US$57.14
52.6% undervalued
intrinsic discount
06 Aug
US$27.07
Loading
1Y
-64.9%
7D
7.4%
Author's Valuation
US$57.1
52.6% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
US$57.1
52.6% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
215b
2014
2017
2020
2023
2025
2026
2028
Revenue US$214.9b
Earnings US$3.0b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
4.37%
Healthcare Services revenue growth rate
0.28%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.74%
Calculation
US$3.03b
Earnings '28
x
9.42x
PE Ratio '28
=
US$28.54b
Market Cap '28
US$28.54b
Market Cap '28
/
399.73m
No. shares '28
=
US$71.39
Share Price '28
US$71.39
Share Price '28
Discounted to 2025 @ 7.77% p.a.
=
US$57.03
Fair Value '25